Supreme Court Seeks Snapdeal’s Reply In Prescription Drug Sale Case
The Supreme Court has requested a response from Snapdeal regarding a plea by the Karnataka government, challenging the quashing of criminal proceedings against the e-commerce platform over the alleged sale of a prescription drug without a license or prescription.
Intelligence analysis by Gemini 2.5 Flash
The case involves the alleged sale of Suhagra-100, a Schedule H prescription medicine, by a third-party seller on Snapdeal without requiring a doctor's prescription. The Karnataka High Court had previously quashed criminal proceedings against Snapdeal, citing safe harbour protection under Section 79 of the IT Act, a ruling now challenged by the state government.
Imagine a big online shop like Snapdeal. Someone bought medicine from a small seller on that shop without a doctor's note, which is against the rules. The government says Snapdeal should have stopped it, but Snapdeal says it's just a platform, like a notice board, and not responsible for what sellers do. Now, a very important court is trying to decide who is right, which will change how all online shops sell things in India.
Analysis
The Legal Battleground
The ongoing legal dispute centers on the alleged sale of Suhagra-100, a Schedule H prescription medicine used for erectile dysfunction, through Snapdeal's online marketplace. The prosecution claims that M/s Herbal Healthcare, a third-party seller on the platform, sold this drug without possessing a valid drug license and, critically, without requiring a doctor's prescription, which is a direct violation of the Drugs and Cosmetics Rules, 1945. This led to a criminal complaint filed by a drugs inspector in Belagavi in 2019, resulting in a judicial magistrate taking cognisance and summoning Snapdeal and its directors, Kunal Bahl and Rohit Kumar Bansal, along with other accused parties. The initial complaint underscores the serious nature of public health regulations, particularly concerning prescription medications, and the potential risks associated with their unregulated sale.
Intermediary Liability and Safe Harbour
Snapdeal and its directors subsequently challenged these proceedings before the Karnataka High Court. In February 2022, the High Court quashed the criminal case, asserting that the magistrate's order lacked adequate application of mind. More significantly, the High Court ruled that Snapdeal, as an online intermediary, was entitled to 'safe harbour' protection under Section 79 of the Information Technology Act, 2000. This provision generally shields online platforms from liability for third-party content or listings, provided they act as neutral facilitators and adhere to due diligence requirements. The Karnataka government, however, has challenged this ruling before the Supreme Court, arguing that safe harbour provisions under the IT Act cannot override or protect intermediaries from prosecution under laws specifically designed to safeguard public health. Additional advocate general Aman Panwar, representing the state, further contended that Snapdeal failed to meet its due diligence obligations under Section 79(2)(c) by allowing the sale of a prescription drug on its platform without the necessary safeguards.
Implications for Indian E-commerce
The Supreme Court's decision in this case holds significant implications for the entire e-commerce landscape in India. It will determine the precise boundaries of intermediary liability, particularly concerning products that fall under stringent sector-specific regulations, such as pharmaceuticals. The outcome will clarify whether e-commerce marketplaces can consistently invoke safe harbour protection when third-party sellers on their platforms are accused of violating public health laws. A ruling that limits safe harbour could compel platforms to implement more rigorous verification processes and oversight mechanisms for sellers of regulated goods, potentially increasing operational costs but enhancing consumer safety. Conversely, an expansive interpretation of safe harbour could raise concerns about accountability and the potential for unregulated sales of sensitive products, impacting public trust and regulatory enforcement. The case, listed for hearing on August 10, is therefore a critical juncture for balancing technological innovation with regulatory compliance and consumer protection in India's rapidly growing digital economy.
Key points
- The Supreme Court has sought Snapdeal's response to Karnataka's plea challenging the quashing of criminal proceedings.
- The case involves the alleged sale of prescription drug Suhagra-100 by a third-party seller on Snapdeal without a license or prescription.
- The Karnataka High Court previously quashed proceedings, citing Snapdeal's safe harbour protection under Section 79 of the IT Act.
- Karnataka argues that safe harbour should not apply to public health law violations and alleges Snapdeal failed its due diligence obligations.
- The case will clarify the extent of intermediary liability for e-commerce platforms selling regulated products in India.
Clearer rules from the Supreme Court could lead to a more robust and trustworthy online pharmacy ecosystem, ensuring consumer safety while allowing e-commerce platforms to operate with defined responsibilities. This clarity could foster innovation within a regulated framework, benefiting both consumers and businesses.
If the Supreme Court's ruling places excessive liability on platforms, it could deter e-commerce companies from hosting certain regulated products, potentially limiting consumer access or stifling growth in online retail. Conversely, an overly broad safe harbour could compromise public health and safety by allowing unregulated sales to persist.
